Given our findings and previous studies showing that NMP was negatively correlated with DTICs, and the treatment with 2 weeks of single-agent ipatasertib induced the decrease of CD4+FOXP3+ regulatory T cells in the tumor microenvironment [61], there may be more advantages to the second category of treatment schedules. This evidence concerns the gene CD4 and neoplasm.